SnapSight
Low-cost, easy-to-use mobile refractometer to expand vision screening in children
Challenge
Based on prevalence trends, myopia and high myopia are increasing at a rapid rate, projected to affect respectively 50% and 10% of the worldwide population by 2050. High myopia, associated with high risk of blindness and serious vision impairments (glaucoma, maculopathies...), can be slowed down when detected early. Highest rate of myopia onset occurs in children between 6 and 10 years old what makes them a particular age group to monitor. However, early detection of myopia remains a challenge.
Solution
Taking advantage of an innovative design, a competitive price (5 times cheaper than competitors), and Artificial Intelligence technology, SnapSight is a digital medical device developed to support new screening protocols and foster continuous eye care.
Objectives, Activities and Results expected / achieved
The projet aims delivering to the European market a reliable and cost-effective tool for myopia screening in children. This device is intended to be used by less optometrically experienced physicians (pediatricians, general practitioner) or non-optometric experts (e.g. nurses) with excellent accuracy performance to limit false referrals, and unnecessary (or unnecessarily early) treatment.
Project Reference
240039Funding
Intervention Region
EuropeTotal Investment
1.829.631,00IPN Investment
94.117,00Total Eligible
1.829.631,00IPN Eligible
94.177,00EC Funding – Total
507.376,00EC Funding – IPN
80.000,00Duration
15 MonthsStart Date
2024-10-01End Date
2025-12-31Approval Date
2024-07-12Consortium
University of Navarra (IESE Business School)Centro Hospitalar e Universitário de Coimbra, EPE
Essilor International
Instituto Pedro Nunes
University of Coimbra
Uppsala Region
Adolphe de Rothschild Foundation Hospital
Keywords
MyopiaVisual screening
Medical device
Artificial Intelligence
